Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases

Condition(s) studied

Investigational drug(s) / intervention(s)

Blood test 4 EDTA tubes: Blood test 4 EDTA tubes for biological check-up

Study summary

Inflammatory bowel diseases, Crohn's disease and haemorrhagic rectocolitis, are pathologies that progress in flare-ups, impacting on patients' quality of life and functional or even vital prognosis. These inflammatory diseases require the use of immunosuppressive and immunomodulatory treatments, the side-effects of which can be significant, and the limited number of which sometimes puts patients and practitioners in a therapeutic impasse from which surgery is the only way out. It is therefore important to be able to develop new therapeutic approaches, ideally better tolerated, that can control inflammation during relapses. Monocytes are one of the main players in the inflammatory reaction. In the laboratory, we have developed a strategy for the metabolic reprogramming of these cells based on the use of oxygen microbubbles to modulate the inflammatory response of monocytes.

Eligibility

Primary outcome measure(s)

• Comparaison of reduction of concentration of inflammatory cytokines and chemokines in cells treated by oxygen microbubbles vs cells not treated — up to 2 years
  Validation of inhibition of the production of inflammatory cytokines and chemokines by the monocytes treated by oxygen microbubbles

Trial sites (1)

More University Hospital, Grenoble trials in France

Other trials for the same condition